Impact of High Dietary Fiber on Microbiome and Vaccine Responses
Not Applicable
Recruiting
- Conditions
- Interventions
- First Posted Date
- 2022-10-04
- Last Posted Date
- 2024-12-05
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 32
- Registration Number
- NCT05565586
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
Precision Optical Guidance for Oral Biopsy
Not Applicable
Recruiting
- Conditions
- Interventions
- First Posted Date
- 2022-09-26
- Last Posted Date
- 2024-02-26
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 90
- Registration Number
- NCT05554133
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
A Virtually Delivered Exercise Intervention To Mitigate Cognitive Deficits From Radiotherapy In AYAs With Brain Tumors
Not Applicable
Suspended
- Conditions
- Interventions
- First Posted Date
- 2022-09-26
- Last Posted Date
- 2024-06-18
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 40
- Registration Number
- NCT05554159
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
E-Health Support Program (PACK Health Program) in Supporting Patient Reported Symptoms in Newly Diagnosed Patients With Breast Cancer
Not Applicable
Completed
- Conditions
- Interventions
- First Posted Date
- 2022-09-22
- Last Posted Date
- 2023-08-14
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 419
- Registration Number
- NCT05549687
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
PRISM: Pre-Operative Radiotherapy and Immunotherapy for Sinonasal Melanoma
- First Posted Date
- 2022-09-21
- Last Posted Date
- 2024-03-29
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 40
- Registration Number
- NCT05546827
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
Time-limited Triplet Combination of Pirtobrutinib, Venetoclax, and Obinutuzumab for Patients With Treatment-naïve Chronic Lymphocytic Leukemia (CLL) or Richter Transformation (RT)
Phase 2
Recruiting
- Conditions
- Interventions
- First Posted Date
- 2022-09-10
- Last Posted Date
- 2024-12-13
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 60
- Registration Number
- NCT05536349
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
Phase 2 Study of Neoadjuvant SAR444245 Plus Cemiplimab in HPV Related Oropharynx Squamous Cell Carcinoma
Phase 2
Withdrawn
- Conditions
- Interventions
- First Posted Date
- 2022-09-10
- Last Posted Date
- 2023-09-13
- Lead Sponsor
- M.D. Anderson Cancer Center
- Registration Number
- NCT05535023
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
Phase II Study of Pirtobrutinib With Venetoclax In Relapsed-Refractory MCL (Mantle Cell Lymphoma) Patients
Phase 2
Recruiting
- Conditions
- Interventions
- First Posted Date
- 2022-09-06
- Last Posted Date
- 2024-11-27
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 30
- Registration Number
- NCT05529069
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
The Attitudes and Beliefs of Hispanic/Latino Individuals Toward Prescription Opioids and Non-Medical Opioid Use
- First Posted Date
- 2022-09-06
- Last Posted Date
- 2024-08-02
- Lead Sponsor
- M.D. Anderson Cancer Center
- Registration Number
- NCT05529082
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
STI-6129 CD38 ADC for the Treatment of Patients With Relapsed or Refractory Systemic ALL Amyloidosis
Phase 1
Withdrawn
- Conditions
- Interventions
- First Posted Date
- 2022-08-29
- Last Posted Date
- 2023-08-31
- Lead Sponsor
- M.D. Anderson Cancer Center
- Registration Number
- NCT05519527
© Copyright 2024. All Rights Reserved by MedPath